However, in ovarian cancer cell lines, treatment with CDK7 inhibitor (THZ1) resulted in decreased expression of MECOM and decreased cell survival with no off-target effect in benign fallopian tube cell lines (Nameki, 2023). This evidence concerns the gene CDK7 and ovarian cancer.